Clostridium Difficile

Feature Article

Biotherapeutics for the Prevention of Clostridium difficile Infection

Biotherapeutics for the Prevention of Clostridium difficile Infection

Experts review biotherapeutics for the prevention of C difficile infection, including probiotics, fecal microbiota transplantation, and nontoxigenic C difficile.

Latest News

Rifaximin Resistance to C difficile in Patients With Cirrhosis

Rifaximin Resistance to C difficile in Patients With Cirrhosis

Study found a considerable proportion of CDI cases occurring in cirrhotic patients receiving rifaximin. CDI was mostly due to selection of rifaximin-resistant C difficile strains.

Lower Risk of C Difficile Infection With Tetracycline Use

Lower Risk of C Difficile Infection With Tetracycline Use

Researchers conducted a systemic review and meta-analysis to determine which antibiotics for systemic use were associated with the lowest risk of C difficile infection.

Multiply Recurrent C difficile Infection Rate 4 Times Higher Than CDI

Multiply Recurrent C difficile Infection Rate 4 Times Higher Than CDI

The rate of multiply recurrent Clostridium difficile (mrCDI) was found to be more than 4 times higher than that of original CDI, with important implications for treatment decisions.

Clostridium difficile Infection Rates Increase in Patients With Cancer

Clostridium difficile Infection Rates Increase in Patients With Cancer

Results of a recent study have shown that infection with Clostridium difficile is increasing in frequency and negatively affects clinical and care outcomes in patients with cancer.

Clostridium difficile Found in 53% of Public Sandboxes

Clostridium difficile Found in 53% of Public Sandboxes

Researchers found a presence of epidemic ribotypes of C difficile found in public children's and dog's sandboxes.

New Method Gauges Persistence of Donor Microbes After Fecal Transplant

New Method Gauges Persistence of Donor Microbes After Fecal Transplant

Therapeutic donor microbes can remain for months or years in patients who've undergone fecal microbiota transplantation.

Ridinilazole Beats Standard of Care in Phase 2 C difficile Study

Ridinilazole Beats Standard of Care in Phase 2 C difficile Study

Recurrent Clostridium difficile infection is associated with a significant economic and mortality burden, but new treatment shows promise.

Oral Prophylactic Therapy Designated Breakthrough Therapy for CDI Prevention

Oral Prophylactic Therapy Designated Breakthrough Therapy for CDI Prevention

The FDA granted Breakthrough Therapy designation to Synthetic Biologics' ribaxamase SYN-004 for Clostridium difficile infection prevention.

Community-based Risk Factors for C difficile Infection in Children

Community-based Risk Factors for C difficile Infection in Children

Community-associated C difficile infection in children was linked to the combination of commonly used antibiotics and exposure to the bacterium in the home and outpatient healthcare settings.

Asymptomatic Carriers of C difficile Increase Infection Risk in Others

Asymptomatic Carriers of C difficile Increase Infection Risk in Others

Asymptomatic carriers of Clostridium difficile in hospitals increase infection risk in other patients.

Sign Up for Free e-newsletters